1. Home
  2. WVE vs FDMT Comparison

WVE vs FDMT Comparison

Compare WVE & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$3.69

Market Cap

673.9M

Sector

Health Care

ML Signal

HOLD

Logo 4D Molecular Therapeutics Inc.

FDMT

4D Molecular Therapeutics Inc.

SELL

Current Price

$12.73

Market Cap

695.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WVE
FDMT
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
673.9M
695.3M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
WVE
FDMT
Price
$3.69
$12.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
21
12
Target Price
$17.11
★ $28.09
AVG Volume (30 Days)
★ 3.0M
970.1K
Earning Date
10-27-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.79
EPS
★ N/A
N/A
Revenue
$3,704,000.00
★ $85,209,000.00
Revenue This Year
$46.45
N/A
Revenue Next Year
N/A
$55.65
P/E Ratio
N/A
★ N/A
Revenue Growth
149.43
★ 230194.60
52 Week Low
$3.04
$6.96
52 Week High
$21.73
$16.93

Technical Indicators

Market Signals
Indicator
WVE
FDMT
Relative Strength Index (RSI) 51.82 49.43
Support Level $3.04 $8.43
Resistance Level $4.07 $13.73
Average True Range (ATR) 0.20 0.90
MACD 0.10 0.05
Stochastic Oscillator 76.83 73.28

Price Performance

Historical Comparison
WVE
FDMT

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Share on Social Networks: